Status:
WITHDRAWN
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
Lead Sponsor:
University of Louisville
Collaborating Sponsors:
Dynavax Technologies Corporation
Conditions:
Hepatitis B Virus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Protection against Hepatitis B infection is a regulatory and safety cornerstone to infection prevention and control programs involving the healthcare workforce in the United States. Until 2018 when a ...
Detailed Description
Background Protection against Hepatitis B infection is a regulatory and safety cornerstone to infection prevention and control programs involving the healthcare workforce in the United States. Until 2...
Eligibility Criteria
Inclusion
- Healthcare personnel age 18-64 years of age who have documentation of prior receipt of two rounds of the traditional 3-dose series of Hepatitis B vaccine and having serologic testing demonstrating quantitative Hepatitis B antibody level of less than 10 iU and a negative Hepatitis B antigen.
Exclusion
- Pregnancy
- Allergy to the adjuvanted vaccine or a vaccine component
- Sensitivity to yeast
- Persons unable to provide consent
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04385524
Start Date
June 1 2020
End Date
February 28 2021
Last Update
April 30 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.